ALLMedicine™ Angina Pectoris Center

Sildenafil, approved two decades ago, is the inhibitor of phosphodiesterase 5 (PDE5). First of all, it was designated for angina pectoris, but soon it showed a wonderful efficacy in erectile dysfunction (ED) and then pulmonary arterial hypertensio...

Jan 20th, 2022 - Noninvasive identification of significant coronary artery disease (CAD) in patients with unstable angina pectoris (UAP) is challenging. Exercise stress testing has been used for years in patients with suspected CAD but has low diagnostic accuracy....

Jan 16th, 2022 - The phenomenon to heal neointimal rupture or thrombus after coronary stenting occurs as well as in native coronary artery. We investigated clinical characteristics and neointimal vulnerability of healed neointima by optical coherence tomography (O...

Jan 12th, 2022 - Using a nationwide epidemiological database, we sought to examine whether there was a sex difference in the association between lipid profiles and subsequent cardiovascular disease (CVD) in young adults. Medical records of 1,909,362 young adults (...

Jan 12th, 2022 - Patients at high risk of having one or more coronary stenosis are evaluated routinely by invasive coronary angiography (CAG). Lesions are often quantified by visual assessment of the angiogram, but physiological assessment of the functional signif...

Sildenafil, approved two decades ago, is the inhibitor of phosphodiesterase 5 (PDE5). First of all, it was designated for angina pectoris, but soon it showed a wonderful efficacy in erectile dysfunction (ED) and then pulmonary arterial hypertensio...

Apr 28th, 2016 - Hypertension Canada's Canadian Hypertension Education Program Guidelines Task Force provides annually updated, evidence-based recommendations to guide the diagnosis, assessment, prevention, and treatment of hypertension. This year, we present 4 ne...

Jul 9th, 2009 - Recommendations for advancing the care of Canadians living with refractory angina pectoris: a Canadian Cardiovascular Society position statement.|2009|McGillion M,L'Allier PL,Arthur H,Watt-Watson J,Svorkdal N,|epidemiology,therapy,epidemiology,

Sildenafil, approved two decades ago, is the inhibitor of phosphodiesterase 5 (PDE5). First of all, it was designated for angina pectoris, but soon it showed a wonderful efficacy in erectile dysfunction (ED) and then pulmonary arterial hypertensio...

Jan 12th, 2022 - Patients at high risk of having one or more coronary stenosis are evaluated routinely by invasive coronary angiography (CAG). Lesions are often quantified by visual assessment of the angiogram, but physiological assessment of the functional signif...

Dec 29th, 2021 - This study is intended to investigate the effect of nitroglycerin on vericiguat in patients with stable coronary artery disease (CAD). Nitroglycerin is the standard therapy to treat acute crisis of angina. Thus there is a high likelihood of co-adm...

Dec 10th, 2021 - THE OPPORTUNITY BEDTIME PRESCRIBING MIGHT PROVIDE: Blood pressure normally exhibits a circadian rhythm with relatively lower pressures during sleep.(Ref 1) Lack of this sleep time "dip" correlates strongly with adverse cardiovascular events and BP...

Nov 8th, 2021 - Study design: After admission, and following clinical and diagnostic evaluation (12-lead electrocardiogram, Doppler echocardiography, symptom-limited cardiopulmonary exercise test and other related laboratory tests), all patients are discharged in...

Sildenafil, approved two decades ago, is the inhibitor of phosphodiesterase 5 (PDE5). First of all, it was designated for angina pectoris, but soon it showed a wonderful efficacy in erectile dysfunction (ED) and then pulmonary arterial hypertensio...

Dec 30th, 2021 - The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaways The study demonstrates that the prevalence of right subclavian plaques is an independent risk factor for future c...

Dec 3rd, 2021 - The addition of darolutamide (Nubeqa) to docetaxel and androgen deprivation therapy (ADT) resulted in a significant improvement in overall survival (OS) compared with docetaxel/ADT alone in patients with metastatic hormone-sensitive prostate cance...

Nov 24th, 2021 - The COVID-19 pandemic spurred the launching or expansion of in-home cancer therapy infusion programs at several oncology centers around the United States, drawing a surge of interest throughout the field as well as opposition from oncologists who ...

Oct 7th, 2021 - The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update for tofacitinib (Xeljanz) stating that individuals aged >65 years, current or past smokers or individuals with other cardiovascular or malignancy risk f...